Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 17, 04 December 2023
Open
Access | Article
The synthetic routes of sorafenib and its applications on hepatocellular carcinoma
* Author to whom correspondence should be addressed.
Abstract
Cancer stands as the second leading cause of global mortality, with a staggering one in five individuals worldwide facing a cancer diagnosis in their lifetime. Addressing cancer prevention has emerged as a significant issue in the field of public health in the 21st century. Hepatocellular carcinoma (HCC) - the primary liver cancer type - not only ranks as one of the top five most frequent cancers globally, but also distressingly represents the fourth leading cause of cancer-related deaths. Notably, it claims the top spot in cancer-related mortality worldwide. Hepatocellular carcinoma is characterized by its high incidence, swift progression, recurrent nature, proclivity for metastasis, and distressingly high mortality rate. A significant proportion of cases trace a three-step path, hepatitis B infection leading to cirrhosis culminating in hepatocellular carcinoma. Sorafenib, a multi-targeted kinase inhibitor, offers promise in combatting this formidable adversary. It works by inhibiting key targets like vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), platelet-derived growth factor receptor β (PDGFR-β), and RAF family kinases, which contributes to its healing effects. This article delves into the synthetic pathway of sorafenib, elucidating its impactful role in cancer treatment, and expounds on its advantageous attributes.
Keywords
Sorafenib, Hepatocellular Carcinoma, Cancer
References
1. Forner A, Reig M and Bruix J 2018 Lancet 391 10127
2. Chidambaranathan-Reghupaty S, Fisher PB and Sarkar D 2021 Adv. Cancer Res. 149 1
3. Li Q, Chen, K, Zhang, T, Jiang, D, Chen, L, Jiang, J, Zhang, C and Li, S 2023 Eur. J. Pharmacol 955 175913
4. Li Y, Yang W, Zheng Y, Dai W, Ji J, Wu L, Cheng Z, Zhang J, Li J, Xu X, Wu J, Yang M, Feng J and Guo C 2023 J. Exp. Clin. Cancer Res. 42 6
5. Yang J D, Hainaut P, Gores G J, Amadou A, Plymoth A and Roberts L R 2019 Nat. Rev. Gastro. Hepat. 16 589
6. Xia S, Pan Y, Liang Y, Xu J and Cai X 2020 E. Bio. Med. 51 102610
7. Breitler S, Oldenhuis N J, Fors B P and Buchwald S L 2011 Org. Lett. 13 3262-326
8. Sun C 2011 Study on the synthesis process of sorafenib (Harbin: Heilongjiang University)
9. Li D, Yao Y, Rao Y, Huang X, Wei L, You Z, Zheng G, Hou X, Su Y, Varghese Z, Moorhead JF, Chen Y and Ruan XZ 2022 J. Exp. Clin. Cancer Res. 41 116
10. Cheng Z, Jiang W and Jin D 2020 Bba-Rev. Cancer 1874 188382
11. Kong F-H, Ye Q-F, Miao X-Y, Liu X, Huang S-Q, Xiong, L Wen, Y and Zhang Z-J 2021 Theranostics 11 5464–5490
12. Abdu S, Juaid N, Amin A, Moulay M and Miled N 2022 Molecules 27 8082
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-197-1
- ISBN (Online)
- 978-1-83558-198-8
- Published Date
- 04 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/17/20240624
- Copyright
- 04 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited